论文部分内容阅读
目的 为研制肺癌疫苗提供适合细胞融合的抗原细胞。方法 用8氮鸟嘌呤(8AG)从小鼠肺癌细胞LA795渐进诱导次黄嘌呤鸟嘌呤转磷酸核糖基酶(HGPRT)缺陷型细胞株ALA9702,并鉴定其生物学性质及成瘤性。结果 ALA9702细胞在20μg/ml8AG培养液中生长了一年,在HAT培养液中不能形成集落,并保持了来源细胞LA795的生物学性质及成瘤性。结论 ALA9702细胞株稳定表现为HGPRT缺陷型小鼠肺癌细胞,为建立有效的特异性肺癌疫苗治疗提供有利的抗原材料
Objective To provide antigen cells suitable for cell fusion for the development of lung cancer vaccines. Methods Apoptotic guanosine transphosphorylation-ribonucleotidylase (HGPRT)-deficient cell line ALA9702 was gradually induced from mouse lung cancer cell line LA795 by 8-azaguanine (8AG), and its biological properties and tumorigenicity were identified. Results ALA9702 cells were grown in 20μg/ml 8AG medium for one year. Colonies could not be formed in HAT medium and the biological properties and tumorigenicity of the source cell LA795 were maintained. Conclusion The ALA9702 cell line is stably expressed as a HGPRT-deficient mouse lung cancer cell, which provides a favorable antigenic material for the establishment of effective specific lung cancer vaccine treatment.